 |
A view onAuthor: Lonza
Discoveries in technology, medicine, and nutrition are emerging with accelerating speed and improving our health and quality of life. Brought to you by Lonza, A View On podcast is a series of short conversations with industry leaders. Join us to discuss new trends that are impacting scientific research, drug discovery and business. The series of monthly conversations with pharma, biotech and nutrition leaders from across industry and academia covers a wide range of topics from 3D bioprinting to therapeutic cannabinoids. In under ten minutes, each podcast takes the audience on a rapid but deep dive into an exciting development that promises to profoundly change or even revolutionize healthcare. Language: en Genres: Life Sciences, Nature, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
A View On Innovating Drug Development and Manufacturing
Episode 9
Sunday, 14 December, 2025
Innovating Drug Development and Manufacturing: How External Collaborations Shape the Future of Biotherapeutics In this episode of A View On, we speak with Andrew Brown, R&D Director at Lonza’s Integrated Biologics, and Zara Asgharpour, Director of External Innovation in Integrated Biologics, about how evolving molecular formats and external innovation are transforming the way biotherapeutics are developed and manufactured. The world of biotherapeutics is in constant evolution, with new molecular formats, scientific insights, and strategic partnerships shaping the medicines of tomorrow. These increasingly complex biologics require new approaches in development and manufacturing, from developing advanced characterization methods to flexible, innovation-driven platforms. Traditionally, biomanufacturing relied on well-established monoclonal antibodies and incremental process improvements. Today, developers are increasingly bringing a far broader range of modalities into the pipeline, each with unique scientific and manufacturability challenges. Meeting these demands requires both internal expertise and collaboration with external innovators. Advances in technology and science are reshaping the design, production, and innovation of biomolecules, making agility, partnerships, and new technologies key to the development of modern biologics.
